Project Grant R41NS137860
Award Date
9/17/24
Completion Date
8/31/26
Dollars Obligated
$350K
Funding Federal Agency
National Institute on Aging
Awarding Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Rezigene, LLC (FXPWSLGW91X5)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $472,695 to 3D Bioanalytix, Inc., a woman-owned small business located in San Diego, CA, to develop a blood-based diagnostic test for detecting neurodegenerative diseases such as Alzheimer's and Parkinson's. The project aims to utilize a novel Covalent Protein Painting (CPP) technology platform to identify and differentiate the misfolded protein aggregates that characterize these...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of small-molecule degraders of the amyloid precursor protein (APP) as potential first-in-class drugs for Alzheimer's disease (AD) therapy. The total award amount is $499,883 and the award period runs from September 1, 2024 to August 31, 2025. The key products and services to be delivered under this grant include: Optimization of lead APP degrader compounds through...
This federal Project Grant award, funded by the National Institute on Aging (part of the Department of Health and Human Services) under the Aging Research program (CFDA 93.866), is focused on evaluating a novel therapeutic approach to target neuroinflammation for protecting against brain aging and Alzheimer's disease-related pathology. The $281,962 award, with an end date of June 30, 2026, will support a series of preclinical studies in aging wild-type mice and transgenic mouse models of amyloid...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,968 to Hager Biosciences, LLC to further develop small molecule inhibitors of the Kv1.3 potassium channel as potential therapeutics for Alzheimer's disease. The key objectives are to: 1) complete in vitro characterization and initial pharmaceutical profiling of lead compound analogs; 2) initiate iterative lead optimization to improve potency and drug-like properties; and...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $632,667 to the Scripps Research Institute for a research project titled "Structure-Function Studies of DELE1-Mediated Activation of the Integrated Stress Response". The project aims to elucidate the mechanisms by which the DELE1 protein relays mitochondrial stress signals to the Integrated Stress Response (ISR) pathway, a key cellular signaling mechanism that declines with aging...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Transchromix LLC provides $994,436.00 in funding to develop novel brain-penetrant drugs for therapeutic targeting of Alzheimer's disease. The research aims to investigate the role of the histone methyltransferase G9A in Alzheimer's disease pathogenesis and the mechanism of action for a brain-penetrant G9A-targeted drug, MS1262, which has shown potential to restore cognitive and affective functions...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Neucyte Inc. a $500,000 Project Grant to develop a nanoluciferase-based microphysiological systems platform for high-throughput screening of potential Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. The project aims to create a scalable, reproducible "mini-brain" assembled organoid (assembloid) model using AD patient-derived and gene-edited induced...
This $514,862 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of an on-chip functional assay to identify candidate microtubule-binding drugs for treating Alzheimer's Disease and related dementias (ADRDs). The award recipient, Neuroindx, a for-profit, woman-owned small business, will create an in vitro platform that replicates key features of the neuronal microtubule microenvironment. This on-chip assay will use generated...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $842,175 to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, to explore the role of the NOX2 enzyme in mediating Alzheimer's disease pathologies. The goal is to assess the therapeutic potential of a novel NOX2 inhibitor (GSK2795039) in mitigating amyloid-beta and tau-induced brain dysfunction, network hyperactivity, and cognitive deficits...
This Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to understand the mechanisms responsible for autophagy defects in neurons affected by Alzheimer's disease (AD). The project will evaluate the effects of clinically relevant inhibitors and modulators on rescuing neuronal autophagy defects and providing synaptoprotective and neuroprotective effects in a transgenic AD mouse model. The total award amount is $749,030.00, with a project period from...